Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-14 pm EST			5-day change	1st Jan Change
218.55 ^USD	+2.29%		+5.33%	+5.61%

Jan. 14	Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide	RE
Jan. 14	Johnson & Johnson Reports 71% Risk Reduction for Tecvayli in Phase 3 Myeloma Study	MT

Press Releases

Jan. 14	TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide	PR
Jan. 13	Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting	PR
Jan. 10	RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer	PR
Jan. 08	Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments	BU
Jan. 07	Bayer takes Pfizer and BioNTech to court over COVID vaccines	AQ
Jan. 07	Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration	BU
Jan. 06	Johnson & Johnson : submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma	PU
Jan. 06	Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study	PR
Jan. 05	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026	AQ
Jan. 02	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026	BU
Dec. 30	Johnson & Johnson acquires Halda Therapeutics for 3 billion dollars; new cancer therapies on the way	AQ
Dec. 29	Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies	BU
Dec. 29	Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study	AQ
Dec. 26	Johnson & Johnson : Statement on the Phase 2b DUPLEX-AD Study	PU
Dec. 22	Johnson & Johnson : European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor	PU
Dec. 22	Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson	AQ
Dec. 19	Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder	AQ
Dec. 19	Johnson & Johnson : Backs HRS Registry to Advance Real-World Evidence in PFA	PU
Dec. 18	Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma	PR
Dec. 17	U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)	PR
Dec. 15	Johnson & Johnson : TECVAYLI® plus DARZALEX FASPRO® combination selected for Commissioner’s National Priority Voucher Pilot program	PU
Dec. 15	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results	BU
Dec. 15	Johnson & Johnson - U.S. FDA approves AKEEGA as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*	AQ
Dec. 15	Johnson & Johnson fined 40 million dollars in case over cancer‑causing talcum powder	AQ
Dec. 13	Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

October 14, 2025 at 12:20 pm EDT

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 09:53 am EDT